July 13, 2026
An Illinois federal judge Friday dismissed a proposed investor class action claiming Assertio misled shareholders about threats to sales of its arthritis drug Indocin, saying the company's public filings explicitly and repeatedly warned that the drug lacked patent protection and faced imminent generic competition at any time.
January 08, 2024
Pharmaceutical company Assertio Inc. has been hit with a proposed class action alleging it misled investors by concealing how reliant it was on an unpatented arthritis medicine, and by overstating the value of an acquisition last year.